Skip to main content

Bleeding

16
Pipeline Programs
14
Companies
17
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
4
8
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
3 programs
2
TamoxifenPhase 4
Tranexamic acidPhase 41 trial
Application of a Junctional TourniquetN/A1 trial
Active Trials
NCT02092415Completed10Est. Mar 2014
NCT06000423Completed65Est. Aug 2025
CSL Seqirus
CSL SeqirusUK - Maidenhead
2 programs
1
1
Prothrombin complex concentratePhase 4
autologous stored plateletsPhase 2
Baxter
BaxterCosta Rica - Cartago
2 programs
1
1
FloSeal MatrixPhase 4
TachoSil®Phase 3
MSD
MSDIreland - Ballydine
2 programs
2
Desogestrel 75 micrograms POPPhase 41 trial
TamoxifenPhase 41 trial
Active Trials
NCT01438736Unknown90
NCT02903121Completed109Est. Jun 2019
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
2
Desogestrel 75 micrograms POPPhase 4
TamoxifenPhase 4
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
7 programs
1
2
3
AndexanetPhase 31 trial
AndexanetPhase 31 trial
AndexanetPhase 31 trial
Andexanet alfaPhase 21 trial
Andexanet alfaPhase 21 trial
+2 more programs
Active Trials
NCT06575517Withdrawn0Est. Jan 2025
NCT03083704Completed153Est. Sep 2017
NCT03330457Terminated18Est. Feb 2016
+4 more trials
CSL Behring
CSL BehringIL - Bradley
2 programs
autologous stored plateletsPHASE_2
Prothrombin complex concentratePHASE_41 trial
Active Trials
NCT02557672Completed106Est. Jan 2022
Baxter International
2 programs
TachoSil®PHASE_3
FloSeal MatrixPHASE_41 trial
Active Trials
NCT00742313Terminated50Est. Sep 2012
Octapharma
OctapharmaAustria - Vienna
1 program
FibrygaN/A1 trial
Active Trials
NCT04106895Completed200Est. Feb 2020
Cellphire Therapeutics
1 program
Thrombosomes®N/A1 trial
Active Trials
NCT04619108No Longer Available
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
central venous catheter applicationN/A1 trial
Active Trials
NCT00448188Completed200Est. Mar 2007
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
autologous stored plateletsPHASE_21 trial
Active Trials
NCT01248351Completed6Est. Mar 2011
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Desogestrel 75 micrograms POPPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Oregon TherapeuticsTranexamic acid
MSDTamoxifen
CSL BehringProthrombin complex concentrate
MSDDesogestrel 75 micrograms POP
Baxter InternationalFloSeal Matrix
AstraZenecaAndexanet
AstraZenecaAndexanet
AstraZenecaAndexanet
AstraZenecaAndexanet alfa
AstraZenecaAndexanet alfa
Novo Nordiskautologous stored platelets
AstraZenecaAndexanet alfa
AstraZenecaA Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants
OctapharmaFibryga
Oregon TherapeuticsApplication of a Junctional Tourniquet

Showing 15 of 16 trials with date data

Clinical Trials (17)

Total enrollment: 1,742 patients across 17 trials

Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects

Start: Jan 2024Est. completion: Aug 202565 patients
Phase 4Completed

Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users

Start: Jan 2017Est. completion: Jun 2019109 patients
Phase 4Completed
NCT02557672CSL BehringProthrombin complex concentrate

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

Start: Aug 2016Est. completion: Jan 2022106 patients
Phase 4Completed
NCT01438736MSDDesogestrel 75 micrograms POP

Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?

Start: Sep 201190 patients
Phase 4Unknown

Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)

Start: Jun 2009Est. completion: Sep 201250 patients
Phase 4Terminated

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

Start: Apr 2015Est. completion: Sep 2020479 patients
Phase 3Completed

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Start: May 2014Est. completion: Aug 201580 patients
Phase 3Completed

A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

Start: Mar 2014Est. completion: Sep 201568 patients
Phase 3Completed

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Start: Aug 2017Est. completion: Aug 2019108 patients
Phase 2Completed

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

Start: Aug 2015Est. completion: Feb 201618 patients
Phase 2Terminated
NCT01248351Novo Nordiskautologous stored platelets

Reversibility of Dual Antiplatelet Therapy by Platelets

Start: Nov 2010Est. completion: Mar 20116 patients
Phase 2Completed

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

Start: Feb 2017Est. completion: Sep 2017153 patients
Phase 1Completed

Thrombosomes for Expanded Access Use

N/ANo Longer Available
NCT06575517AstraZenecaA Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants

A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)

Start: Jan 2025Est. completion: Jan 20250
N/AWithdrawn

Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data

Start: Feb 2019Est. completion: Feb 2020200 patients
N/ACompleted
NCT02092415Oregon TherapeuticsApplication of a Junctional Tourniquet

Assessment of Limb Perfusion During Junctional Tourniquet

Start: Sep 2013Est. completion: Mar 201410 patients
N/ACompleted
NCT00448188Heidelberg Pharmacentral venous catheter application

Bleeding Risk in CVCs

Start: Nov 2005Est. completion: Mar 2007200 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.